Janus Henderson Group Plc - Jul 2, 2024 Form 4 Insider Report for ARCA biopharma, Inc. (ABIO)

Role
10%+ Owner
Signature
/s/ Michelle Rosenberg, CAO, General Counsel & Company Secretary
Stock symbol
ABIO
Transactions as of
Jul 2, 2024
Transactions value $
$1,427,345
Form type
4
Date filed
7/12/2024, 07:38 PM
Next filing
Jul 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABIO Common Stock Purchase $590K +166K +11.2% $3.55 1.65M Jul 3, 2024 By Fund F1
transaction ABIO Common Stock Purchase $80K +23.3K +1.41% $3.43 1.67M Jul 5, 2024 By Fund F1
transaction ABIO Common Stock Purchase $17.1K +5K +0.3% $3.41 1.68M Jul 5, 2024 By Fund F1
transaction ABIO Common Stock Purchase $102K +29.9K +1.78% $3.41 1.71M Jul 8, 2024 By Fund F1
transaction ABIO Common Stock Purchase $62.2K +17.6K +1.03% $3.54 1.72M Jul 8, 2024 By Fund F1
transaction ABIO Common Stock Purchase $58.1K +16.9K +0.98% $3.43 1.74M Jul 9, 2024 By Fund F1
transaction ABIO Common Stock Purchase $116K +33.5K +1.92% $3.46 1.77M Jul 10, 2024 By Fund F1
transaction ABIO Common Stock Purchase $76.1K +22K +1.24% $3.46 1.8M Jul 10, 2024 By Fund F1
transaction ABIO Common Stock Purchase $326K +94.5K +5.26% $3.45 1.89M Jul 11, 2024 By Fund F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.